Assessment of quality of data submitted for NICE technology appraisals over two decades.

ABSTRACT:

Background

The National Institute for Health and Care Excellence (NICE) pioneered the Health Technology Assessment (HTA) processes and methodologies. Technology appraisals (TAs) focus on pharmaceutical products and clinical and economic data, which are presented by the product manufacturers to the NICE appraisal committee for decision-making. Uncertainty in data reduces the chance of a positive outcome from the HTA process or requires a higher discount.

Objective

To investigate the quality of clinical data (comparator, quality of life (QoL), randomised controlled trials (RCTs) and overall quality of evidence) submitted by the manufacturers to NICE.

Design

This retrospective evaluation analysed active TAs published between 2000 and 2019 (up to TA600).

Methods

Fo

SUBMITTER: Osipenko L 

PROVIDER: S-EPMC10870012 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature